Survey of a treatment for Acquired Hemophilia A
Official title: General Use-results Survey of OBIZUR for I.V. Injection (All-case Surveillance)
Run by Takeda · NCT06461533 · Data updated 2026-11-12
This study is trying out a new injection treatment for people with Acquired Hemophilia A in Japan to see if it helps reduce bleeding and what side effects it might have.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 25 (estimated) |
| Sponsor | Takeda Industry-sponsored |
| Locations | 1 site (Tokyo, Tokyo) |
| Status | Recruiting |
| Started | June 10, 2024 |
| Main results expected | May 31, 2028 |
| Study ends | May 31, 2028 |
| Registry record updated | August 7, 2026 |
| Trial ID | NCT06461533 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are individuals diagnosed with Acquired Hemophilia A who are receiving treatment with Susoctocog Alfa.
✕Probably not a fit
Patients who do not have Acquired Hemophilia A or are not treated with Susoctocog Alfa will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study surveys the use of Susoctocog Alfa (Genetical Recombination) intravenous injection in participants with Acquired Hemophilia A in Japan. The study aims to monitor side effects and assess the effectiveness of the treatment in improving bleeding events. Participants will receive the treatment according to their clinic's standard practice, and the study will track outcomes for up to 90 days post-treatment. The sponsor will provide guidelines for clinics on how to document the treatment process and results.
Why it matters
Potential benefit: If successful, this study could enhance the understanding of Susoctocog Alfa's effectiveness and safety in treating Acquired Hemophilia A.
How similar studies have gone: While this study focuses on a specific treatment, similar observational studies have shown promise in monitoring treatment effects in hemophilia management.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: \- All participants with Acquired Haemophilia A, treated with Susoctocog Alfa (Genetical Recombination). Exclusion Criteria: \- None
Where it's running
-
Takeda selected site
Tokyo, Tokyo, Japan Recruiting
Study contacts
- Study coordinator: Takeda Contact
- Email: medinfoUS@takeda.com
- Phone: +1-877-825-3327
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
OBIZUR treatment for adults with acquired hemophilia A in South Korea
This project will test how safe OBIZUR is and whether it helps control bleeding in adults in South Korea who have acquired hemophilia A.
-
Observational study of blood clotting and bleeding disorders in Chinese patients
This study looks at blood clotting and bleeding problems in Chinese patients to see how common they are and what factors might affect them.
-
Using a CD38 antibody with corticosteroids to treat acquired hemophilia A
This study is testing if a combination of a new antibody treatment and steroids can help people with acquired hemophilia A stop bleeding and stay healthy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.